EP0306525A4 - Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes mellitus - Google Patents

Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes mellitus

Info

Publication number
EP0306525A4
EP0306525A4 EP19880903550 EP88903550A EP0306525A4 EP 0306525 A4 EP0306525 A4 EP 0306525A4 EP 19880903550 EP19880903550 EP 19880903550 EP 88903550 A EP88903550 A EP 88903550A EP 0306525 A4 EP0306525 A4 EP 0306525A4
Authority
EP
European Patent Office
Prior art keywords
use
diabetes mellitus
insulin sensitivity
reductase inhibitors
aldose reductase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19880903550
Other versions
EP0306525A1 (en
Inventor
Billie M. York, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Laboratories Inc
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US2851287A priority Critical
Priority to US28512 priority
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Publication of EP0306525A1 publication Critical patent/EP0306525A1/en
Publication of EP0306525A4 publication Critical patent/EP0306525A4/en
Application status is Withdrawn legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
EP19880903550 1987-03-20 1988-03-18 Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes mellitus Withdrawn EP0306525A4 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US2851287A true 1987-03-20 1987-03-20
US28512 1987-03-20

Publications (2)

Publication Number Publication Date
EP0306525A1 EP0306525A1 (en) 1989-03-15
EP0306525A4 true EP0306525A4 (en) 1991-04-24

Family

ID=21843865

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19880903550 Withdrawn EP0306525A4 (en) 1987-03-20 1988-03-18 Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes mellitus

Country Status (5)

Country Link
EP (1) EP0306525A4 (en)
JP (1) JPH01503460A (en)
AU (1) AU598366B2 (en)
CA (1) CA1310269C (en)
WO (1) WO1988006887A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
KR100343944B1 (en) * 2001-02-14 2002-07-24 주식회사 에이.비.아이 Composition of L-2-oxothiazolidine-4-carboxylic acid or its saits as non-insulin dependent diabetes therapeutic agent

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
US4436745A (en) * 1982-04-15 1984-03-13 Alcon Laboratories, Inc. Method of inhibiting aldose reductase activity
US4438272A (en) * 1982-04-15 1984-03-20 Alcon Laboratories, Inc. Spiro-(fluoren-9,4'-imidazolidine)-2',5'-diones
US4537892A (en) * 1983-09-14 1985-08-27 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase
US4600717A (en) * 1984-04-11 1986-07-15 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in ophthalmic wound healing
US4609663A (en) * 1984-09-11 1986-09-02 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in glaucoma therapy
US4864028A (en) * 1983-09-14 1989-09-05 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147797A (en) * 1978-08-11 1979-04-03 Pfizer Inc. Spiro-furanohydantoin derivatives
US4251258A (en) * 1978-09-29 1981-02-17 Monsanto Company N-(Substituted carbonyl) derivatives of N-phosphinylmethylglycinates and the herbicidal use thereof
US4226875A (en) * 1979-04-02 1980-10-07 Pfizer Inc. Novel spiro-oxazolidinediones
US4235911A (en) * 1979-06-13 1980-11-25 Pfizer Inc. Hydantoin derivatives
US4254108A (en) * 1979-11-08 1981-03-03 Ayerst, Mckenna & Harrison Inc. Thioxo-1H-benz[de]isoquinoline-2(3H)-acetic acid derivatives and antidiabetic use thereof
US4430337A (en) * 1982-06-23 1984-02-07 Pfizer Inc. Alicyclic substituted oxazolidine-2,4-diones having hypoglycemic activity
JPS6178725A (en) * 1984-09-20 1986-04-22 American Home Prod Stabilized tolrestat rotation isomer composition
US4604406A (en) * 1984-11-16 1986-08-05 Ayerst, Mckenna & Harrison, Inc. N-[6-methoxy-5-(perfluoroalkyl)-1-naphtholyl]-N-methylglycines and their thionaphthoyl analogs
US4575507A (en) * 1985-05-29 1986-03-11 Pfizer Inc. Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
US4436745A (en) * 1982-04-15 1984-03-13 Alcon Laboratories, Inc. Method of inhibiting aldose reductase activity
US4438272A (en) * 1982-04-15 1984-03-20 Alcon Laboratories, Inc. Spiro-(fluoren-9,4'-imidazolidine)-2',5'-diones
US4537892A (en) * 1983-09-14 1985-08-27 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase
US4864028A (en) * 1983-09-14 1989-09-05 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives
US4600717A (en) * 1984-04-11 1986-07-15 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in ophthalmic wound healing
US4609663A (en) * 1984-09-11 1986-09-02 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in glaucoma therapy

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
Biochimica et Biophysica Acta, Vol. 870, 1986, pages 302-311, Elsevier Science Publishers B.V. (Biomedical Division); S.K. SRIVASTAVA et al.: "Hyperglycemia-induced activation of human erythrocyte aldose reductase and alterations in kinetic properties", Abstract. *
Chem. Pharm. Bull., Vol. 32, No. 5, 1984, pages 2030-2032; I. MIWA et al.: "Hypoglycemic activity of aldose reductase inhibitor, 1 (p-bromophenyl) sulfonyl hydantoin", whole article. *
CHEMICAL ABSTRACTS, Vol. 105, No. 11, 15th September 1986, page 337, Abstract No. 102604d, Columbus, Ohio, US; & JP,A,61 078 725 (AMERICAN HOME PRODUCTS CORP.) 22-04-1986, whole Abstract. *
Exp. Eye Res., Vol. 46, 1988, pages 517-530, Academic Press Ltd; M.F. LOU et al.: "Glutathione depletion in the lens of galactosemic and diabetic rats", whole article. *
Horm. Metab. Res., Vol. 10, 1978, pages 280-282, Georg Thieme Publishers; W. LIPPMANN et al.: "Effect of alrestatin on arginine-induced secretion of glycagon and insulin in the rat", Summary. *
Metabolism, Vol. 34, No. 10, October 1985, pages 885-892, Grune & Stratton, Inc.; N. SIMARD-DUQUESNE et al.: "The effects of a new aldose reductase inhibitor (Tolrestat) in galactosemic and diabetic rats", whole article. *
Metabolism, Vol. 34, No. 4, April 1985, pages 336-344, Grune & Stratton, Inc.; D. STRIBLING et al.: "Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat", Abstract. *
Metabolism, Vol. 35, No. 4, suppl. 1, April 1986, pages 83-92, Grune & Stratton, Inc.; J.B. JASPAN et al.: "Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes", Abstract. *
Metabolism, Vol. 36, No. 5, May 1987, pages 486-490, Grune & Stratton, Inc.; B. WALKER GRIFFIN et al.: "Effects of two new aldose reductase inhibitors, AL-1567 and AL-1576, in diabetic rats", whole article. *
Pharmacology, Vol. 32, 1986, pages 52-60; A. BEYER-MEARS et al.: "Diminished proteinuria in diabetes mellitus by sorbinil, an aldose reductase inhibitor", Abstract. *
See also references of WO8806887A1 *

Also Published As

Publication number Publication date
CA1310269C (en) 1992-11-17
AU1549088A (en) 1988-10-10
EP0306525A1 (en) 1989-03-15
WO1988006887A1 (en) 1988-09-22
AU598366B2 (en) 1990-06-21
JPH01503460A (en) 1989-11-22

Similar Documents

Publication Publication Date Title
AU546417B2 (en) Glucose sensor
GB2175993B (en) Improvements in or relating to dual fuel injectors
AU591890B2 (en) Improvements in or relating to 3-Aryluracils
AU521624B2 (en) Transcuteneous measurement of the partial oxygen pressure in blood
GB2225764B (en) Improvements in and relating to drug capsules
AU611181B2 (en) Improvements in and relating to packaging
AU554029B2 (en) Glucose determination via conversion to fructoseamine
AU588860B2 (en) Improvements in or relating to organic compounds
AU638747B2 (en) Improvements in or relating to organic compounds
IL87020D0 (en) Acrylic acid derivatives and their use as pesticides
EP0307316A3 (en) Vehicle window to be glued on instantly
GB2199319B (en) Improvements in and relating to glass forming
DE3064330D1 (en) Adhesive compositions and their use in bonding fluorinated rubbers to substrates
JPS63303918A (en) Transparent antiperspirant stick composition
AU6952687A (en) Process for the preparation of granules containing an active substance and to the use therefor as speckles for treating substrates
EP0101681A4 (en) Antibody to a mediator activity composition and its use in a pharmaceutical composition.
AU5042190A (en) Non-invasive measurement of blood glucose
GR880100011A (en) Improvements relating to organic compounds
PT8849U (en) Filter used in a cartridge to contain a drink
PL163079B1 (en) Method for preparation of a pharmaceutical to be slowly dissolved in the human organism
AU7437087A (en) Oxygen measurement using visible radiation
NZ244576A (en) Syringe barrel with contrast band opposite indicia to improve readability
EP0517050A3 (en) Test-strip containing merocyanine and nitro or nitroso substituted polyhalogenated phenol-sulfonephthaleins as protein indicators
GB8903804D0 (en) Improvements in or relating to organic compounds
AU6450986A (en) Improvements in or relating to organic compounds

Legal Events

Date Code Title Description
AK Designated contracting states:

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19890519

AK Designated contracting states:

Kind code of ref document: A4

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

A4 Despatch of supplementary search report

Effective date: 19910306

DA4 Despatch of supplementary search report (deleted)
RA4 Despatch of supplementary search report

Effective date: 19910805

17Q First examination report

Effective date: 19920610

18D Deemed to be withdrawn

Effective date: 19930511